None

Novavax raises $12.2 million

Vaccines company Novavax Inc. (NASDAQ:NVAX) raised $12.2 million through the sale of 10 million shares at $1.22 in a private placement to RA Capital Healthcare Fund. The price is a 5% premium to Novav...

Novavax takes bigger 2Q loss as costs grow

Vaccine developer Novavax Inc. said Friday it took a wider loss in the second quarter as its research and development costs increased.Novavax is studying vaccines for illnesses including seasonal inf...

Novavax raises $27M

Novavax Inc. (NASDAQ:NVAX) said late Tuesday that it raised $27 million through the sale of 12.4 million shares at $2.18 to RA Capital Management; Camber Capital Management; and Ayer Capital Managemen...

Novavax gains $2M from nonprofit to study RSV vaccine

The Program for Appropriate Technology in Health agreed to provide Novavax about $2 million initially to support a midstage t -More- 

Novavax and Cadila in publicprivate malaria vaccine collaboration

USA-based clinical-stage firm Novavax (Nasdaq: NVAX), CPL Biologicals (CPLB) - a joint-venture biotechnology company established in 2009 by Novavax and India's Cadila Pharmaceuticals, and the Internat...

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities

Novavax announce promising RSV vaccine Phase II results

Novavax have reported positive results of a Phase II clinical trial of its respiratory syncytial virus (RSV) vaccine candidate as a maternal immunization strategy. Novavax [...]

Novavax vaccine shows positive results in trial, shares up

(Reuters) - Novavax Inc said its vaccine to treat a virus that causes infections in the respiratory tract met trial objectives and showed a good safety profile, sending its shares up three percent aft...

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

We performed a Phase 1 randomized, observer-blinded, placebo-controlled trial to evaluate the safety and immunogenicity of a recombinant respiratory syncytial virus (RSV) fusion (F) protein nanopartic...